European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 96

Vaccines 96

Express Pharma

FEBRUARY 26, 2024

The partnership will build upon existing manufacturing capacity for the vaccine at Takeda’s facility in Singen, Germany and Takeda’s long-term partnership with IDT Biologika GmbH Takeda and Biological E. Limited, which has deep expertise in vaccine manufacturing and longstanding support of public health programs around the world.

Vaccines 92

Vaccines Packaging 92

STAT

SEPTEMBER 29, 2022

The Covid-19 pandemic set back many of the global health goals for 2030. One of the most feasible to recover is the target of eliminating human deaths from rabies , thanks to an effective, inexpensive vaccine for dogs.

Vaccines 272

Vaccines 272

STAT

JANUARY 12, 2023

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.

Vaccines 245

Vaccines 245

The Guardian - Pharmaceutical Industry

APRIL 7, 2023

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives ‘A silver lining’: how Covid ushered in a vaccines golden era Millions of lives could be saved by a groundbreaking set of new vaccines for a range of conditions including cancer, experts have said.

Vaccines 92

Vaccines 92

European Pharmaceutical Review

JULY 12, 2023

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Vaccines 91

Vaccines Immunity Immunization 91

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 92

Vaccines Immunity Immunization 92

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 80

Vaccines Immunity Immunization Documentation 80

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunity Immunization 78

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Pfizer’s RSVpreF vaccine is in hot pursuit of GSK’s shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults.

Vaccines 101

Vaccines 101

Express Pharma

DECEMBER 8, 2023

The 12 blockbuster drugs include nine medicines and vaccines with 2 billion to 5 euros ($2.15-$5.38 The 12 blockbuster drugs include nine medicines and vaccines with 2 billion to 5 euros ($2.15-$5.38 billion) of annual sales by 2030.

Vaccines 91

Vaccines Compounding 91

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Vaccines 137

Vaccines Hospitals 137

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

pharmaphorum

SEPTEMBER 8, 2022

On the strength of phase 2 data, the FDA has awarded coveted breakthrough status to Pfizer’s vaccine against Group B Streptococcus (GBS), given to expectant mothers to prevent invasive infections in newborns and young infants. The post FDA gives Pfizer’s Group B strep vaccine breakthrough status appeared first on.

Vaccines 52

Vaccines 52

Express Pharma

SEPTEMBER 20, 2023

The free vaccination camps will be run with support of Brihanmumbai Municipal Corporation (BMC). The ‘Stop Rabies’ initiative aligns with India’s National Action Plan for Dog-Mediated Rabies Elimination by 2030. It adopts a two-pronged approach of vaccination and education.

Vaccines 87

Vaccines 87

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 91

Biosimilars Vaccines 91

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. If successfully developed, this means cancer vaccines could become part of standard care. Signing of this agreement builds on a memorandum of understanding signed in January.

Vaccines 86

Vaccines 86

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. BioNTech to support trial access for cancer immunotherapies Developing an mRNA cancer vaccine In terms of disease indication, melanoma remains the primary focus of advanced mRNA-based therapies, GlobalData reported.

Immunity 87

Immunity Immunization Vaccines 87

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 110

Vaccines Immunity Immunization Drug Development 110

European Pharmaceutical Review

JANUARY 6, 2023

BioNTech has signed an agreement with the UK Government to help accelerate clinical trials for personalised mRNA immunotherapies, with the aim to provide personalised cancer therapies for up to 10,000 patients by the end of 2030. Infectious disease vaccines. The collaboration will focus on three strategic pillars.

Vaccines 52

Vaccines 52

Pharmacy Times

NOVEMBER 4, 2022

WHO has released a global plan for hepatitis B elimination by 2030, including goals to increase pediatric and maternal immunization and to improve screening and treatment.

Vaccines 26

Vaccines Immunity Immunization 26

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Immunity 115

Immunity Immunization Vaccines 115

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.

Vaccines 88

Vaccines Communication Documentation Compounding 88

Express Pharma

MAY 7, 2024

The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.

Insurance Coverage and Processing 101

Insurance Coverage and Processing Vaccines Drug Pricing 101

pharmaphorum

JUNE 22, 2022

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. Construction of the facility is expected to start later this year, said the government, with the first mRNA vaccines due to be produced there in 2025.

Vaccines 58

Vaccines 58

Pharmaceutical Technology

MARCH 31, 2023

The company will construct the new advanced mRNA facility, which is claimed to be Moderna’s first mRNA manufacturing facility in Africa and is expected to have the capacity to produce up to 500 million vaccine doses annually. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 105

Vaccines 105

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunity Immunization Hospitals 145

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

Express Pharma

NOVEMBER 24, 2023

With objectives laid down during the G20 presidency, the industry in India is poised to scale to $65 billion by 2024 and surpass $130 billion by 2030, driven by heightened pharma innovation, technological advancements, and a focus on breakthrough products.

Packaging 92

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 92

Express Pharma

NOVEMBER 28, 2023

Dr Ranga Reddy, President, Infection Control Academy of India said, “AMR poses a threat to various aspects of life, undermining the 2030 Sustainable Development Goals, especially in regions with inadequate sanitation. The concept of healthy aging can be adopted by staying healthy and by vaccinating against the communicable diseases.”

Hospitals 79

Hospitals Dosage Compounding Communication 79

Pharmaceutical Technology

JUNE 27, 2022

The international agency had previously set a target of eliminating viral hepatitis by 2030. As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

JULY 21, 2022

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.

Drug Pricing 52

Drug Pricing Vaccines 52

Express Pharma

NOVEMBER 22, 2023

At the recent CII 5th Life Sciences Summit 2023, Arunish Chawla, Secretary, Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, said, “India has the potential to grow 3-4 times in value by achieving a shift from 10 per cent share of Pharma and MedTech in the manufacturing sector in 2020 to a 20 per cent share in 2030.”

Vaccines 82

Vaccines 82

pharmaphorum

AUGUST 4, 2022

Thousands of people in the UK will be screened for hepatitis C virus in a new pilot aimed at expanding use of antiviral therapies to eradicate the infectious – and eliminate it altogether by 2030.

Hospitals 52

Hospitals Vaccines 52